0001209191-23-053670.txt : 20231026
0001209191-23-053670.hdr.sgml : 20231026
20231026164606
ACCESSION NUMBER: 0001209191-23-053670
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231024
FILED AS OF DATE: 20231026
DATE AS OF CHANGE: 20231026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thiara Parvinder
CENTRAL INDEX KEY: 0001995535
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231350804
MAIL ADDRESS:
STREET 1: C/O TOURMALINE BIO, INC.
STREET 2: 27 WEST 24TH STREET, SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tourmaline Bio, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-481-9832
MAIL ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: Talaris Therapeutics, Inc.
DATE OF NAME CHANGE: 20201007
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-24
0
0001827506
Tourmaline Bio, Inc.
TRML
0001995535
Thiara Parvinder
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702
NEW YORK
NY
10010
1
0
0
0
0
Common Stock
2023-10-24
4
P
0
5000
10.66
A
80782
D
Common Stock
2023-10-25
4
P
0
2000
12.12
A
82782
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $12.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Brad Middlekauff, Attorney-in-Fact
2023-10-26